Metastatic Castration-Resistant Prostate Cancer Market Size was nearly USD 6.8 billion in 2023

DelveInsight’s latest analysis highlights that the total metastatic castration-resistant prostate cancer (mCRPC) market size across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan - was estimated at nearly USD 6.8 billion in 2023. This market is projected to demonstrate robust positive growth through 2034, fueled by the increasing prevalence of prostate cancer, particularly in emerging and aging populations, lifestyle-related risk factors, and improved access to healthcare and advanced diagnostics.

Metastatic castration-resistant prostate cancer represents one of the most challenging stages of prostate cancer, characterized by disease progression despite androgen deprivation therapy (ADT). Among the two advanced forms of prostate cancer - metastatic castration-sensitive prostate cancer (mCSPC) and mCRPC - mCRPC was the more prevalent condition in 2023 across the 7MM, underlining its substantial clinical and economic burden.

 

United States Dominates the Global Metastatic Castration-Resistant Prostate Cancer Market

In 2023, the United States accounted for approximately 64% of the total mCRPC market share within the 7MM, making it the single largest contributor to global revenues. The strong market position of the US is supported by high disease awareness, early adoption of innovative therapies, favorable reimbursement frameworks, and a well-established oncology infrastructure.

DelveInsight estimates that the US mCRPC market alone was valued at approximately USD 4.4 billion in 2023, and this figure is expected to rise steadily during the forecast period (2024–2034). Within the EU4, Germany led the mCRPC market in 2023, while Spain reported the smallest market size. Japan continues to show consistent growth driven by an aging population and improving cancer management strategies.

 

Diverse and Evolving Metastatic Castration-Resistant Prostate Cancer Therapeutic Landscape

The mCRPC treatment market currently features a broad spectrum of therapeutic classes, reflecting significant scientific progress over the past decade. Available treatment options include:

• Androgen receptor (AR) inhibitors
• PARP inhibitors
• CYP17 inhibitors
• Microtubule inhibitors
• Radioligand therapies
• Immunotherapies and chemotherapies

This diversity has enabled physicians to tailor treatment strategies across different lines of therapy based on disease progression, biomarker status, and patient characteristics.

Among androgen deprivation therapies (ADTs), XTANDI (enzalutamide) and abiraterone acetate continue to dominate the market. These agents are heavily prescribed in first- and second-line mCRPC settings, supported by extensive clinical evidence and real-world usage. In 2023, XTANDI accounted for nearly 41% of the total mCRPC market share across the 7MM, making it the leading therapy in this space.

 

Recent Approvals Strengthen First-Line and Precision Treatment Options

The mCRPC market has witnessed several important regulatory approvals in recent years, significantly expanding treatment options - particularly for biomarker-selected patient populations.

In 2023, AKEEGA (niraparib + abiraterone acetate) and the combination of TALZENNA (talazoparib) with XTANDI (enzalutamide) were approved for the treatment of patients with mCRPC, marking a critical milestone for PARP inhibitor-based combination strategies. These approvals reinforce the growing importance of precision medicine and genetic testing, particularly in patients with BRCA or homologous recombination repair (HRR) gene mutations.

Other established therapies such as XTANDI, PROVENGE, JEVTANA, ZYTIGA, and LYNPARZA continue to play a central role in mCRPC management. The market has also been reshaped by Novartis’ PSMA-targeted radioligand therapy PLUVICTO, approved in 2022, which generated unexpectedly strong revenues from third-line mCRPC settings and rapidly became a key growth driver.

 

Radioligand Therapies Emerge as a Transformational Modality

Radioligand therapies are increasingly viewed as one of the most promising innovations in mCRPC treatment. PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) has demonstrated meaningful survival benefits in patients with PSMA-positive mCRPC who have limited treatment options, establishing a new standard of care in later-line settings.

DelveInsight projects that by 2034, PLUVICTO is expected to generate the highest mCRPC revenues in the United States, reflecting strong uptake, label expansions, and increasing physician confidence in radioligand approaches. In the EU4 and the UK, XTANDI is anticipated to retain its leadership position by 2034, supported by its broad indications and long-standing clinical use.

 

Strong and Competitive Metastatic Castration-Resistant Prostate Cancer Pipeline Across Treatment Lines

Quantitatively, the mCRPC pipeline is considered robust, with numerous late-stage assets under development across first-line, second-line, and third-line settings. Key companies actively advancing their pipelines include Merck, Novartis, AstraZeneca, Bristol-Myers Squibb, Pfizer, ESSA Pharma, Arvinas, Lantheus, Eli Lilly/POINT Biopharma, Ipsen, Curium, Telix International, and others.

• First-line mCRPC candidates include Merck and Orion’s opevesostat (MK-5684), ESSA Pharma’s masofaniten, and Tavanta’s TAVT-45.
• In the second-line setting, CABOMETYX (cabozantinib) is anticipated to be among the first emerging therapies to receive regulatory approval.
• In third-line and later settings, promising assets include 177Lu-PNT2002 (Lantheus and Eli Lilly/POINT Biopharma), actinium-225–based PSMA-targeting agents such as FPI-2265, and PROTAC AR degraders like ARV-766 being developed by Arvinas and Novartis.

These emerging therapies target novel mechanisms such as CYP11A1 inhibition, PSMA targeting, AKT inhibition, PROTAC-mediated androgen receptor degradation, and immune modulation, reflecting a shift toward more durable and personalized treatment strategies.

 

Metastatic Castration-Resistant Prostate Cancer Epidemiology Highlights Growing Patient Pool

According to DelveInsight’s epidemiological analysis, the 7MM recorded approximately 7.28 million prevalent cases of prostate cancer in 2023, a number expected to rise steadily through 2034 due to demographic aging and improved diagnostic capabilities.

In the United States:

• Approximately 40% of prostate cancer cases are diagnosed in individuals aged 65–74 years.
• Around 56% of cases are localized or locally advanced, while nearly 11% present with metastatic disease.
• The total number of mCRPC cases in the US was estimated at around 51,100 in 2023, with further growth anticipated over the forecast period.

Among EU4 and the UK, Germany reported the highest number of mCRPC cases in 2023, while Spain had the lowest. These epidemiological trends underscore the expanding addressable patient population for mCRPC therapies.

 

Recent Developments Reflect Rapid Metastatic Castration-Resistant Prostate Cancer Market Evolution

The mCRPC landscape continues to evolve rapidly, as evidenced by multiple regulatory and clinical milestones:

• In March 2025, the FDA expanded PLUVICTO’s indication to include PSMA-positive mCRPC patients suitable for delaying chemotherapy.
• In September 2024, Ipsen’s Phase III CONTACT-02 trial of CABOMETYX plus atezolizumab met its progression-free survival endpoint.
• In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for mCRPC.
• Multiple Phase II and III trials initiated in 2024 and 2025 highlight sustained investment and innovation across the pipeline.

 

Metastatic Castration-Resistant Prostate Cancer Market Outlook: Growth Driven by Innovation and Label Expansions

Overall, the metastatic castration-resistant prostate cancer market is expected to witness significant growth through 2034. Key factors driving this expansion include:

• Increasing prevalence of advanced prostate cancer
• Extensive market penetration of approved therapies
• Label expansions into earlier treatment lines
• Entry of novel targeted and radioligand therapies
• Growing emphasis on biomarker-driven treatment decisions

Despite these advances, mCRPC remains a lethal condition, and substantial unmet needs persist - particularly for patients who progress after multiple lines of therapy. Continued innovation, improved access to genetic testing, and favorable reimbursement strategies will be critical to improving patient outcomes and sustaining market growth.

 

About the Metastatic Castration-Resistant Prostate Cancer Report

DelveInsight’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Market Insights, Epidemiology, and Market Forecast – 2034” report delivers a comprehensive analysis of disease epidemiology, current and emerging therapies, real-world prescription patterns, competitive dynamics, and market forecasts across the 7MM from 2020 to 2034. The report also incorporates expert opinions, SWOT analysis, and insights into market access and reimbursement trends to support strategic decision-making.